TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

CARTITUDE-1 trial: Is JNJ-4528 safe and efficacious for patients with RRMM?

Featured:

Deepu MadduriDeepu Madduri

Dec 13, 2019


The Multiple Myeloma Hub is pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Deepu Madduri, Icahn School of Medicine at Mount Sinai, New York, US, answers the question: Based on the CARTITUDE-1 trial, is JNJ-4528 safe and efficacious for patients with relapsed/refractory multiple myeloma?

JNJ-4528, is a second-generation chimeric antigen T-cell receptor containing two BCMA-targeting single-domain antibodies. Based on the CARTITUDE-1 trial, JNJ-4528 delivers early and deep responses with a manageable safety profile in patients with refractory multiple myeloma.

CARTITUDE-1 trial: Is JNJ-4528 safe and efficacious for patients with RRMM?